After a double-digit run-up in the last quarter of 2017, shares of�Wheaton Precious Metals (NYSE:WPM) dealt a heavy blow to investors when they nosedived in February alongside the broader market. The sell-off was clearly overdone, as the stock soon bounced back to regain all of its losses and more, swiftly closing the gap with peers Franco-Nevada (NYSE:FNV) and Royal Gold (NASDAQ:RGLD). As of this writing, Wheaton's up nearly 16% from its February bottom.
Does that make Wheaton Precious Metals stock a buy at current prices?
The silver liningBecause silver contributes a major chunk to Wheaton's revenues, declining silver production for the better part of 2017 kept investors on tenterhooks and drove the stock lower.�
Note that production here doesn't mean extraction of metals, as is typically the case with gold and silver miners. Wheaton, Royal Gold, and Franco-Nevada are precious metals streaming companies, which means they buy metals from third-party miners at discounted prices under streaming agreements in exchange for funding the miners upfront. In other words, these companies' sales are hit if their mining partners face production hurdles. Last year, for example, lower production from gold miner�Goldcorp's Penasquito mine hit Wheaton and Royal Gold, both of which have streaming agreements with Goldcorp.
Top Gold Stocks For 2018: Insperity, Inc.(NSP)
Advisors' Opinion:- [By Joseph Griffin]
Shares of Insperity Inc (NYSE:NSP) have been given a consensus rating of “Buy” by the six analysts that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $86.75.
- [By Shane Hupp]
Get a free copy of the Zacks research report on Insperity (NSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Max Byerly]
Get a free copy of the Zacks research report on Insperity (NSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Stephan Byrd]
Wells Fargo & Company MN trimmed its holdings in shares of Insperity Inc (NYSE:NSP) by 17.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 176,365 shares of the business services provider’s stock after selling 37,265 shares during the period. Wells Fargo & Company MN owned about 0.42% of Insperity worth $12,266,000 at the end of the most recent reporting period.
- [By Ethan Ryder]
Naturally Splendid Enterprises Ltd (CVE:NSP) insider Sead Hamzagic sold 141,500 shares of the company’s stock in a transaction dated Monday, June 11th. The stock was sold at an average price of C$0.21, for a total value of C$29,715.00.
Top Gold Stocks For 2018: Northrop Grumman Corporation(NOC)
Advisors' Opinion:- [By Logan Wallace]
State of Wisconsin Investment Board boosted its holdings in Northrop Grumman (NYSE:NOC) by 1.4% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 151,723 shares of the aerospace company’s stock after buying an additional 2,063 shares during the period. State of Wisconsin Investment Board owned 0.09% of Northrop Grumman worth $52,970,000 at the end of the most recent reporting period.
- [By Rich Smith]
Orbital plans to begin ground-testing the rocket next year, by which time Orbital ATK will probably have been subsumed into new owner Northrop Grumman (NYSE:NOC). In anticipation of testing beginning, Orbital gave NGL an official name last month: OmegA.
- [By Todd Shriber, ETF Professor]
Code Pink takes issue with BlackRock's investments in aerospace and defense companies such as General Dynamics Corp.(NYSE: GD), Lockheed Martin Corp. (NYSE: LMT) and Northrop Grumman Corp. (NYSE: NOC).
- [By Lisa Levin] Companies Reporting Before The Bell Thermo Fisher Scientific Inc. (NYSE: TMO) is projected to report quarterly earnings at $2.4 per share on revenue of $5.63 billion. Ford Motor Company (NYSE: F) is expected to report quarterly earnings at $0.41 per share on revenue of $37.16 billion. Twitter, Inc. (NYSE: TWTR) is projected to report quarterly earnings at $0.11 per share on revenue of $605.26 million. Comcast Corporation (NASDAQ: CMCSA) is expected to report quarterly earnings at $0.59 per share on revenue of $22.75 billion. General Dynamics Corporation (NYSE: GD) is estimated to report quarterly earnings at $2.52 per share on revenue of $7.6 billion. The Boeing Company (NYSE: BA) is expected to report quarterly earnings at $2.58 per share on revenue of $22.24 billion. Anthem, Inc. (NYSE: ANTM) is estimated to report quarterly earnings at $4.91 per share on revenue of $22.52 billion. Viacom, Inc. (NASDAQ: VIAB) is projected to report quarterly earnings at $0.79 per share on revenue of $3.04 billion. Northrop Grumman Corporation (NYSE: NOC) is estimated to report quarterly earnings at $3.61 per share on revenue of $6.61 billion. Rockwell Automation Inc. (NYSE: ROK) is expected to report quarterly earnings at $1.81 per share on revenue of $1.66 billion. Wipro Limited (NYSE: WIT) is projected to report quarterly earnings at $0.07 per share on revenue of $2.15 billion. The Goodyear Tire & Rubber Company (NASDAQ: GT) is expected to report quarterly earnings at $0.46 per share on revenue of $3.82 billion. Owens Corning (NYSE: OC) is projected to report quarterly earnings at $0.97 per share on revenue of $1.62 billion. T. Rowe Price Group, Inc. (NASDAQ: TROW) is estimated to report quarterly earnings at $1.71 per share on revenue of $1.29 billion. Dr Pepper Snapple Group, Inc. (NYSE: DPS) is expected to report quarterly earnings at $1.04 per share on revenue of $1.57 billion. Sirius XM Holdings Inc. (NASDAQ: SI
- [By Max Byerly]
TT International lessened its stake in Northrop Grumman (NYSE:NOC) by 40.1% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,047 shares of the aerospace company’s stock after selling 2,040 shares during the quarter. TT International’s holdings in Northrop Grumman were worth $1,063,000 as of its most recent filing with the SEC.
- [By ]
Moreno found similar patterns in Northrop Grumman (NOC) and Lockheed Martin (LMT) , both with pullbacks in February that seem to now be at a crossroads.
Top Gold Stocks For 2018: Restoration Hardware Holdings Inc.(RH)
Advisors' Opinion:- [By Isaac Pino, CPA]
While much has been said about upscale furniture retailer RH's (NYSE:RH) soaring stock price recently, less attention has been paid to the story behind the company's radical overhaul.CEO Gary Friedman is making some intriguing contrarian bets for RH, pursuing experiential stores in an industry that's downsizing its bricks-and-mortar footprint. Meanwhile, Friedman's embracing a membership model, physical catalogs, and a premium market at a time when most everyone else is slashing costs, running promotions, and scrambling to move online.In the company's most recent conference call, Friedman shared his thoughts on the company's business model, the retail industry's herd mentality, and the habits and desires of furniture shoppers. Here are the three takeaways I found most interesting:
- [By Max Byerly]
Aperio Group LLC boosted its holdings in Restoration Hardware Holdings, Inc common stock (NYSE:RH) by 10.3% during the 1st quarter, HoldingsChannel.com reports. The fund owned 8,532 shares of the company’s stock after acquiring an additional 799 shares during the quarter. Aperio Group LLC’s holdings in Restoration Hardware Holdings, Inc common stock were worth $813,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
- [By Garrett Baldwin]
Today, Bill offers our readers a few of his favorites as Trump meets with Kim Jong Un.�Here's how to cash in regardless of how this summit turns out in the long run.
The Top Stock Market Stories for Tuesday Last night, President Trump met North Korean leader Kim Jong Un in Singapore. This was the first meeting between a sitting American president and a North Korean leader. Following the agreement, analysts noted that the document signed by both parties included no concrete details for achieving denuclearization on the Korean Peninsula. Trump responded to criticism by saying he is fully confident that the Korean dictatorship will follow through. A U.S. district court will rule on whether to approve an $85 billion merger between AT&T Inc. (NYSE: T) and Time Warner Inc. (NYSE: TWX). The decision comes after about six weeks of debate in a courtroom. The ruling will likely have a significant impact on the proposed bid by The Walt Disney Co. (NYSE: DIS) for media giant Twenty-First Century Fox Inc.�(NYSE: FOXA). The Fed Open Market Committee kicks off its June meeting today. The U.S. central bank is expected to raise interest rates for the second time in 2018. On Wednesday, U.S. Federal Reserve Chair Jerome Powell will likely announce a hike of 0.25% to the benchmark rate to 2%. This would also mark the seventh hike since December 2015. Markets will be looking for clues during Powell's conference to determine how many additional times the Fed plans to raise interest rates during the final six months of the year. Three Stocks to Watch Today: RH, TSLA, GE Restoration Hardware Holdings Inc. (NYSE: RH) stock popped more than 20% in pre-market hours after the company reported very strong profits for the quarter. The retailer reported earnings per share of $1.33, well above the $1.02 anticipated by analysts. The company also reported a strong second-quarter outlook, news that reduced concerns about it falling short of revenue expectations. Tesla Inc. (Nasdaq: TS
Top Gold Stocks For 2018: Genomic Health, Inc.(GHDX)
Advisors' Opinion:- [By Logan Wallace]
Genomic Health (NASDAQ:GHDX) – Equities researchers at Piper Jaffray issued their Q2 2018 earnings per share (EPS) estimates for shares of Genomic Health in a research report issued on Wednesday, May 2nd. Piper Jaffray analyst W. Quirk expects that the medical research company will post earnings of $0.06 per share for the quarter. Piper Jaffray has a “Hold” rating and a $33.00 price target on the stock. Piper Jaffray also issued estimates for Genomic Health’s Q3 2018 earnings at $0.11 EPS, Q4 2018 earnings at $0.14 EPS, FY2018 earnings at $0.44 EPS, Q1 2019 earnings at $0.16 EPS, Q2 2019 earnings at $0.18 EPS, Q3 2019 earnings at $0.12 EPS, Q4 2019 earnings at $0.15 EPS and FY2019 earnings at $0.62 EPS.
- [By Brian Orelli]
Shares of Genomic Health (NASDAQ:GHDX) are up 18.6% at 1:23 p.m. EDT after data from the Trial Assigning Individualized Options for Treatment (TAILORx) trial was presented at the American Society of Clinical Oncology meeting and published in The New England Journal of Medicine.
- [By Brian Orelli]
Cancer-test maker Genomic Health (NASDAQ:GHDX) started the year on a high note, posting double-digit revenue growth, and would have turned a profit if not for an $8.5 million�one-time charge for stopping development of the Oncotype SEQ Liquid Select test, which was announced on the last quarterly call.
- [By Stephan Byrd]
ELEKTA AB/ADR (OTCMKTS: EKTAY) and Genomic Health (NASDAQ:GHDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
- [By Shane Hupp]
Genomic Health (NASDAQ: GHDX) and CareDx (NASDAQ:CDNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, valuation and earnings.
- [By Stephan Byrd]
Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 10,000 shares of Genomic Health stock in a transaction on Thursday, June 14th. The shares were sold at an average price of $48.89, for a total value of $488,900.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Top Gold Stocks For 2018: Medley Capital Corporation(MCC)
Advisors' Opinion:- [By Joseph Griffin]
Get a free copy of the Zacks research report on Medley Capital (MCC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top Gold Stocks For 2018: Dermira, Inc.(DERM)
Advisors' Opinion:- [By Maxx Chatsko]
Shares of skincare pharmaceutical specialist Dermira (NASDAQ:DERM) dropped nearly 23% today after the company hosted its investor and analyst day for 2018. Investors were none too thrilled with the presentations given -- and were only reminded about the stinging failure of a once-promising acne drug DRM01 in March. Shares slipped over 64% on that news.
- [By WWW.GURUFOCUS.COM]
For the details of Novo A's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Novo+A
These are the top 5 holdings of Novo AInogen Inc (INGN) - 3,549,320 shares, 59.83% of the total portfolio. Acceleron Pharma Inc (XLRN) - 1,553,937 shares, 9.34% of the total portfolio. Dermira Inc (DERM) - 1,984,364 shares, 7.81% of the total portfolio. Shares added by 3.27%Corvus Pharmaceuticals Inc (CRVS) - 3,244,046 shares, 4.76% of the total portfolio. Akebia Therapeutics Inc (AKBA) - 2,225,000 shares, 4 - [By Paul Ausick]
Dermira Inc. (NASDAQ: DERM) traded down about 64% Monday and posted a new 52-week low of $8.95 after closing Friday at $25.16. The stock’s 52-week high is $38.39. Volume was about 40 times the daily average of around 615,000 shares. The company’s trial of a new acne treatment failed to meet the designated endpoints.
- [By Chris Lange]
Dermira Inc. (NASDAQ: DERM) watched its shares absolutely collapse early on Monday after the firm reported disappointing results from its late-stage trials in patients with acne vulgaris. Essentially, Dermira��s Phase 3 trials of the investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints.
- [By Shane Hupp]
Dermira (NASDAQ:DERM) has been given a $20.00 price target by Cantor Fitzgerald in a research note issued to investors on Thursday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective indicates a potential upside of 146.61% from the company’s previous close. Cantor Fitzgerald also issued estimates for Dermira’s FY2018 earnings at ($4.63) EPS.
No comments:
Post a Comment